glp-1 medications approved for diabetes and weight loss 2025 What to Make of the Coverage Cost Landscape HR Newsletter: GLP-1s and Group

Monoacylglycerol binds to GPR119 in L cells to promote the release of GLP-1, GIP and insulin ( 2+ were observed following GPBA-R activation in single GLUTag cell, and bile acid and GPBA-RA increased GLP-1 secretion in intestinal cultures (Parker et al., 2012b)

Reader insights There are no comments for this story Be the first to respond and start the conversation.

Eli Lilly announced Phase 3 ATTAIN-1 trial results for orforglipron, an oral GLP-1 receptor agonist, showing significant weight loss in adults with obesity or overweight without diabetes

Metabolism, 164, 156113

This is particularly relevant during dose escalation periods when gastrointestinal symptoms tend to be most pronounced

[DOI] [PMC free article] [PubMed] [Google Scholar] 348.Meurot, C